Bead-Coated Immune Complex Assay for Immunoglobulin Potency Testing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for a reliable and sensitive method to determine the functional potency and integrity of plasma-derived immunoglobulin compositions, particularly those containing IgM and IgA, as existing assays do not adequately assess their immunomodulatory activities, which are crucial for therapeutic efficacy, especially in conditions like COVID-19.
Innovation Solution
A method involving beads coated with antigens and specifically bound antibodies is used to test the potency of immunoglobulin compositions by measuring their ability to inhibit effector functions of immune cells, such as cytokine secretion by HL60 cells, providing a sensitive and reproducible assay for immunomodulatory potency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing assays are used to test immunoglobulin compositions, then the testing process is simple, but the ability to assess immunomodulatory activities is insufficient
Solution Approach 1:
The patent introduces bead-coated immune complexes as an intermediary system to bridge the gap between simple testing and reliable immunomodulatory assessment. The beads serve as a mediator that presents antigens in a controlled manner, enabling the test immunoglobulin to interact with immune effector cells in a standardized format that reliably measures immunomodulatory activity without requiring complex in vivo models
Solution Approach 2:
The patent replaces complex in vivo immunomodulatory assessment with an in vitro cell-based assay system. By substituting whole-organism complexity with a controlled cell culture system using immune effector cells and bead-coated immune complexes, the method achieves reliable immunomodulatory measurement through simplified, standardized laboratory procedures
2Manufacturing precision
If standardized immunoglobulin compositions are prepared without rigorous potency testing, then the manufacturing process is faster, but the functional potency and integrity cannot be ensured
Solution Approach 1:
The patent implements preliminary potency testing using bead-coated immune complexes before final product release. This preliminary assessment of immunomodulatory activity using standardized bead systems allows manufacturers to ensure functional potency and integrity are achieved before completing the manufacturing process, preventing the need for time-consuming post-manufacturing adjustments
Solution Approach 2:
The patent establishes standardized parameters for immunomodulatory potency testing using bead-coated immune complexes and immune effector cells. By defining specific measurable parameters (such as inhibition of effector functions) and standardized test conditions, the method enables rapid yet precise assessment of functional potency, allowing standardized compositions to be approved more efficiently
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method effectively characterizes and quality controls immunoglobulin compositions, demonstrating enhanced immunomodulatory potency of IgM and IgA-containing compositions like IVIG-AM, which can inhibit inflammatory cytokine release, thereby offering a promising therapeutic approach for conditions characterized by excessive inflammation.
Implementation Method 1
providing a bead coated with an antigen and an antibody specifically bound to said antigen
Implementation Method 2
contacting said bead with said immunoglobulin test composition and with an immune effector cell expressing at least one Fc-Receptor (FcR)
Implementation Method 3
The potency is tested by the capability of the composition to inhibit an effector function of an Fc-receptor expressing immune effector cell, such as a neutrophil, e.g., a HL60 cell, preferably, production of an inflammatory cytokine such as IL-8
Data Source
AI summary
The present invention relates to the field of immunotherapeutics, in particular to a method for characterization and/or quality control of immunotherapeutics. It provides a method of testing potency of an immunoglobulin composition, e.g., plasma or a plasma-derived immunoglobulin composition such as an intravenous immunoglobulin composition (IVIG), as well as to use of a bead coated with an antigen and an antibody specifically bound to said antigen for testing po-tency of an immunoglobulin composition. Said immunoglobulin composition, or immunoglobulin test composition can be an IVIG, particularly and IgA- and/or IgM enriched (also sometimes re-ferred to as IVIG-AM). The potency is tested by the capability of the composition to inhibit an ef-fector function of an Fc-receptor expressing immune effector cell, such as a neutrophil, e.g., a HL60 cell, preferably, production of an inflammatory cytokine such as IL-8. The invention also relates to a method of preparing a standardized immunoglobulin composition, to a kit for carry-ing out the method, as well as a composition. The immunoglobulin compositions obtainable from said method may be used, e.g., in the treatment of inflammation, e.g., in the context of COVID-19 or pneumonia, e.g., severe community-acquired pneumonia.